Celcuity Inc.

Celcuity Inc. is a clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, focused on transforming cancer treatment through the development of targeted therapies for multiple solid tumor indications. The company's mission centers on addressing cellular abnormalities that drive tumor growth, particularly those involving the PI3K/AKT/mTOR (PAM) pathway.

Celcuity's lead product candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor designed to comprehensively block the PAM pathway. This investigational drug is being developed for the treatment of various cancers, including hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer, and metastatic castration-resistant prostate cancer. The company also utilizes its proprietary CELsignia diagnostic platform, which analyzes live patient tumor cells to identify specific abnormal cellular processes and match patients with appropriate targeted therapies.

In recent developments, Celcuity announced positive topline results in May 2026 from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib in HR+/HER2- advanced breast cancer. The U.S. FDA has granted Priority Review for gedatolisib's New Drug Application (NDA) for PIK3CA wild-type advanced breast cancer, with a Prescription Drug User Fee Act (PDUFA) goal date of July 17, 2026. The company plans to submit a supplemental NDA (sNDA) for the PIK3CA mutant cohort. Led by Co-Founder, Chairman, and CEO Brian Sullivan, Celcuity is actively preparing for the potential commercialization of gedatolisib, which analysts project could address a total addressable market exceeding $5 billion with potential peak annual revenues of $2.5-$3 billion.

Latest updates

Celcuity's PI3K/AKT/mTOR Inhibitor Shows Clinically Meaningful Survival Benefit in Breast Cancer Trial

Event summary

  • Celcuity's Phase 3 VIKTORIA-1 trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in PIK3CA mutant HR+/HER2- advanced breast cancer patients treated with gedatolisib plus fulvestrant, with or without palbociclib, compared to alpelisib and fulvestrant.
  • A secondary analysis of gedatolisib plus fulvestrant alone also showed a statistically significant and clinically meaningful improvement in PFS compared to alpelisib and fulvestrant.
  • Celcuity intends to submit data to the FDA for a supplemental New Drug Application (sNDA) and to other regulatory authorities.
  • The FDA has granted Priority Review to Celcuity’s NDA for gedatolisib in patients with HR+/HER2-/PIK3CA wild-type ABC, with a PDUFA goal date of July 17, 2026.

The big picture

Celcuity's results address a significant unmet need in advanced breast cancer, where existing therapies targeting PI3Kα or AKT have demonstrated limited efficacy and often lead to resistance. The demonstrated efficacy of a multi-target PAM inhibitor like gedatolisib, particularly in the PIK3CA mutant cohort, represents a potential paradigm shift in treatment approaches. The company's broader strategy to expand gedatolisib's application could unlock significant additional revenue streams, but also introduces increased development risk.

What we're watching

Regulatory Risk
The FDA’s review of the sNDA will be critical; any unexpected requests for additional data or concerns about safety could delay or impact approval.
Commercial Adoption
The success of gedatolisib will depend on physician and patient adoption, which will be influenced by its pricing, reimbursement, and the availability of companion diagnostics to identify eligible patients.
Pipeline Expansion
Celcuity's stated intention to explore gedatolisib for other cancer types and patient populations will be a key indicator of the drug’s long-term commercial potential and the company’s strategic direction.
CID: 1707